Usefulness of Routine Laboratory Tests for Follow up of Patients Receiving Outpatient Parenteral Antimicrobial Therapy Run by Infectious Diseases Fellows
Division of Infectious Diseases, Doisy Research Center, Saint Louis University, 1100 S. Grand Blvd., Saint Louis, MO 63104, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(2), 330; https://doi.org/10.3390/antibiotics12020330
Submission received: 26 December 2022
/
Revised: 1 February 2023
/
Accepted: 2 February 2023
/
Published: 4 February 2023
(This article belongs to the Special Issue Diagnostics, Treatment and Prevention of Bacterial Infections)
Abstract
:Background: The infectious disease society of America (IDSA) recommends routine laboratory tests for all patients receiving outpatient parenteral antimicrobial therapy (OPAT) to monitor for adverse events. There are no data to support how often patients should take monitoring laboratory tests. In addition, the relevance of different laboratory tests commonly used for OPAT follow up is not clearly known. Methods: We conducted a retrospective observational cohort study over a 7-year study interval (1 January 2014 to 31 December 2021). Clinical data were obtained to identify the risk factors associated with abnormal laboratory tests and determine if abnormal laboratory tests led to antibiotic change or hospital readmission. Results: Two hundred and forty-six patients met the inclusion criteria for this study. In our multivariate analysis, the Charlson comorbidity index (CCI) of 0–4 (aOR 0.39, 95%Cl 0.18–0.86), the use of ceftriaxone without vancomycin (aOR 0.47, 95%Cl 0.24–0.91) and an OPAT duration of 2–4 weeks (aOR 0.47, 95%Cl 0.24–0.91) were associated with a lower risk of OPAT complications. A CCI of 5 or more (aOR 2.5, 95%Cl (1.1–5.7)) and an OPAT duration of 5 or more weeks (aOR 2.7, 95% Cl 1.3–5.6) were associated with a higher risk of OPAT complications. An abnormal complete metabolic panel or vancomycin levels, but not an abnormal complete blood count, were associated with antibiotic change or readmission. Conclusion: Patients with fewer comorbidities, ceftriaxone and short OPAT durations are at lower risk for OPAT complications. These patients could be followed with less frequent laboratory monitoring.
1. Introduction
Outpatient parenteral antimicrobial therapy (OPAT) is a preferred method to administer long-term intravenous (IV) antibiotic therapy for various infections. OPAT reduces the length of hospital stays and costs while improving patient satisfaction [1,2]. The use of IV antibiotics in an unmonitored setting puts patients at risk for adverse events and hospital readmission. The rate of adverse events ranges from 11.8–63.2% depending on patient factors and the antibiotic used [3,4,5]. Vancomycin and semisynthetic penicillins are typically associated with a higher risk of adverse reactions [3,4,6,7,8,9]. This risk can be mitigated by regular laboratory monitoring, a shorter OPAT duration and frequent outpatient follow ups [1]. It is not always feasible for patients to visit an infusion center or have frequent physician visits. Therefore, monitoring laboratory tests and the use of home nursing visits with regular reporting to outpatient clinics where patients have regular follow ups could be an alternative strategy [10,11].
The IDSA OPAT guidelines on monitoring laboratory results for individual antibiotics are based on known adverse events associated with that antibiotic [1]. The guidelines recommend at least a weekly complete blood count with differential (CBC) and serum creatinine for all parenteral antibiotics. CBCs monitor secondary infections, hypersensitivity drug reactions and drug-related cytopenia. Serum creatinine helps monitor nephrotoxicity and guides appropriate antibiotics dose adjustment. The guidelines recommended monitoring serum electrolytes and liver enzyme levels when certain antibiotics such as beta-lactams are used. A complete metabolic panel (CMP) can monitor renal function, electrolytes, and liver enzyme levels while a basic metabolic panel (BMP) only monitors renal function and electrolyte levels. The guidelines also recommend weekly therapeutic drug monitoring while using aminoglycosides and vancomycin even in patients with stable renal function and serum drug levels [8,9,12]. There are no good data on how often OPAT monitoring laboratory tests should be obtained. However, the guidelines do suggest monitoring patients with fewer comorbidities and short courses of OPAT less frequently. This study was conducted with the objectives of determining the relevance of different laboratory tests for OPAT follow up and identifying predictors of a low risk of OPAT complications that allow for less-frequent laboratory monitoring.
2. Results
2.1. Baseline Characteristics
After reviewing the medical records of 326 patients, 246 eligible patients were included. A total of 116 patients had OPAT-related complications and 130 patients had no complications. Demographic and clinical data characteristics of the two groups of patients are shown in Table 1. The median age was 55 years (IQR 40–65) and 56% were male. Patients often had multiple comorbidities. Those without OPAT complications were more likely to have no comorbidities. Of the 246, 126 (51.2%) had bone and joint infections, 27 (11%) had CNS infections, 22 (8.9%) had abdominal infections and 21 (8.5%) had endocarditis.
Infections with gram-positive bacteria other than MRSA and polymicrobial infections were the most common infections identified in 91/26 (37%) and 53/246 (21.5) patients, respectively. Beta-lactams with or without vancomycin were the most common antibiotics prescribed. Ceftriaxone and ertapenem were the most frequently used beta-lactams. Two-hundred and nineteen (89%) patients received one or two antibiotics for OPAT and 175/246 (71.1%) were receiving OPAT for 5 weeks or more. The majority of patients (i.e., 109/116, 93.2% of patients with complications and 123/130, 94.6% of patients without complications) received OPAT at home. Seventy-eight (67.3%) patients with complications and 102 (78.5%) without complications followed up in the outpatient clinic within the first 3 weeks of discharge. Anemia was the common baseline laboratory abnormality, seen in 85 (73.3) patients with complications and 86 (66.2%) patients without complications.
2.2. OPAT Complications
Table 1 shows the predictors of OPAT complications. Penicillin and semisynthetic penicillin (i.e., ampicillin and nafcillin) had the highest OPAT complications compared to cephalosporins and ertapenem (15/29, 51.7% vs. 41/156, 26.2%). A univariate analysis found that patients were less likely to have an OPAT complication if they had no comorbidities, CCI scores < 5, genitourinary infections, receive a beta-lactam antibiotic without vancomycin, received ceftriaxone or ertapenem, experienced OPAT durations of 2–4 weeks, had a clinic follow up within 1–3 weeks of discharge and no baseline laboratory abnormalities. Conversely, patients with OPAT complications were likely to have CCI scores of five or more, an MRSA infection, received vancomycin, OPAT durations of 5 weeks or more and a clinic follow up after 3 weeks post hospital discharge. Our multivariate regression model found that CCI scores < 5, the use of ceftriaxone and OPAT durations of 2–4 weeks were associated with fewer complications with OPAT. Conversely, CCI scores of five or more and OPAT durations of 5 weeks or more were associated with OPAT complications.
2.3. Laboratory Abnormalities and Risk of Readmission to Hospital or Antibiotic Change
There was no patient who had abnormal urinalysis results while receiving OPAT. Table 2 shows a list of laboratory abnormalities, the time of detection of these abnormalities and their association with hospital readmission. The majority of laboratory abnormalities were on CMP or vancomycin troughs. A total of 21 of the 163 (12.9%) laboratory abnormalities were creatinine elevations, which suggested acute kidney injuries, and eleven patients required hospitalization. Nine of those with acute kidney injuries were on vancomycin, two were on vancomycin and two were on on nafcillin. A total of 41 (25.2%) patients developed electrolyte abnormalities, with 15 requiring outpatient supplementation and 25 with no intervention. Five patients with electrolyte abnormalities required readmission to the hospital. We noted eleven incidences of elevated liver enzymes with seven that resolved spontaneously. One patient was readmitted for nafcillin-induced liver injury and three on vancomycin required changing antibiotics. Patients on vancomycin often required dose adjustments for abnormal vancomycin levels. Thirteen patients changed vancomycin to daptomycin due to OPAT complications. A total of 22 patients (8.9%) had CBC abnormalities, and 7 of these 22 patients (31.8%) required an intervention. Eosinophilia was the most common CBC abnormality seen in 14 patients. Only 3/14 (21.4%) patients with eosinophilia were associated with hypersensitivity reactions. There were three incidences of leukopenia, one in a patient who was on nafcillin and two in patients who were on rifampin. One patient was readmitted for acute blood loss anemia. Two of nine (22.2%) patients on daptomycin developed significantly elevated creatine kinase requiring a switch to vancomycin.
We assessed the risk of readmission or antibiotic change based on laboratory abnormalities in our patient population. Fifty-two patients required readmission or antibiotic change (Table 3). In a multivariate analysis that included CCL scores, late clinic follow ups, abnormal CMPs, abnormal CBCs and abnormal vancomycin levels, only abnormal CMPs were associated with hospitalization or changing antibiotics (aOR: 5.7, 95%Cl 2.85–11.24). Abnormal vancomycin troughs and CBC were not significantly associated with a need for hospitalization or change in antibiotics.
3. Discussion
OPAT is a health care cost-saving strategy for patients who require long-term parenteral antibiotics [13,14]. Patient satisfaction is high in OPAT users [15] and the successful completion of OPAT requires minimizing adverse events [16]. Therefore, OPAT programs utilize regular laboratory tests to monitor adverse events and manage the adverse events timely. The IDSA OPAT guidelines suggest the use of CBC with differential, BMP and liver profile testing to monitor adverse events [1]. However, the type of laboratory tests used for OPAT monitoring may vary from program to program depending on the resources and type of drugs used [1,17]. Our results showed that urine analysis will not help with monitoring and confirmed the importance of regular laboratory tests, particularly electrolytes, renal function, and liver enzymes, albeit at a different frequency than what was previously suggested to potentially minimize the cost for OPAT programs.
In our study, only 14 (5.7%) patients received OPAT at a skilled nursing facility (SNF). The risk of rehospitalization did not differ between the group who received OPAT at home and those receiving OPAT at SNF. This could be because of the small number of patients who had OPAT at SNF. A prior study showed that patients who received OPAT at SNF had a 46% increased risk of rehospitalization compared to patients who received OPAT at home [18,19].
Our results showed that patients with few comorbidities (CCL < 5), patients who used ceftriaxone alone and patients with an OPAT duration of 4 weeks or less could have laboratory monitoring less frequently than once a week. This study suggests that patients on ceftriaxone are less likely to experience OPAT complications and could require less frequent monitoring. Ertapenem was associated with more complications, but this could be incidental since it was more commonly used with vancomycin. Vancomycin use has a strong association with adverse events, as has been shown in multiple studies, so patients should have at least weekly vancomycin troughs and serum creatinine levels [8,12].
In our study, penicillin and semisynthetic penicillin were the most common causes of abnormal laboratory results. It has been previously reported that semisynthetic penicillins are associated with higher rates of adverse events compared to cephalosporins and ertapenem [4,6,7,20]. In our study, CBC abnormalities were less frequently associated with hospitalization or a change in antibiotics compared to CMP abnormalities. Eosinophilia was the most common CBC abnormality. The 56.9% rate of eosinophilia seen in our OPAT cohort was much higher than the 25% rate of eosinophilia reported previously [21]. While most patients with eosinophilia do not develop an associated clinical abnormality, eosinophilia increases the hazard rate of developing a rash and experiencing renal injury [21].
Metronidazole and rifampin were common oral antibiotics used with either vancomycin or beta-lactams for broader coverage and for a better activity in biofilm, respectively. Neither were associated with OPAT complications that warranted hospitalization, but two patients developed leukopenia while on rifampin. Metronidazole is generally safe for use during OPAT, and to our knowledge, there is only one report that showed an unexpected increase in AKI in patients receiving metronidazole, but these patients were also receiving vancomycin which was likely the main cause for AKI [22]. Rifampin, when used during OPAT, is safe, but adverse events arising from interactions with medications for other comorbidities should be monitored [23].
In addition to weekly laboratory follow ups, other different strategies have been employed to decrease rehospitalization rates. It has been reported that regular telephone calls after hospital discharge to ensure adherence is associated with lower readmission rates [24]. Because of the use of central lines and long antibiotic courses, OPAT patients could be at risk of vascular access complications and C-difficile diarrhea. In one study, vascular access complications (i.e., occlusion, line dislodgement, leaking or bleeding, pain and infection) that require intervention have been seen in about 9% of OPAT courses [25]. Long OPAT durations and IVDU have been found to increase the risk of vascular access complications [25]. Despite the perceived risk, it was found that the incidence of Clostridium difficile infection in OPAT patients was low. A single-center study of OPAT patients conducted at Cleveland clinic, USA found that there were 0.26 cases of C-difficile infection per 1000 patient days [26]. Furthermore, OPAT patients who receive antibiotics at home have a significantly lower risk of experiencing C. difficile diarrhea compared to patients who complete similar long-course antibiotics in the hospital [13], indicating that OPAT minimizes hospital-acquired infections.
In our study, early clinic follow ups (i.e., before 3 weeks after hospital discharge) were associated with fewer OPAT complications, whereas late clinic follow ups were associated with more OPAT complications. The time from discharge to clinic follow up is known to have an association with an increased risk of OPAT complications [27]. Patients that would require weekly or more frequent OPAT laboratory monitoring include patients with multiple comorbidities (CCL ≥ 5) and OPAT courses of 5 weeks or more. In one case series, patients with multiple comorbidities tended to have more antibiotic side effects [28]. In fact, some comorbidities such as cardiac and renal failure are considered a relative contraindication to OPAT by some because these comorbidities increase the risk of OPAT failure [29].
4. Materials and Methods
Settings: This study was conducted at Saint Louis University Hospital, a 350-bed tertiary academic medical center, over a 7-year interval (1 January 2014 to 31 December 2021). Patients that were discharged home and receiving OPAT received antibiotics from a home infusion company for self-administration. A home health care nurse visited weekly to maintain the peripherally inserted central catheter (PICC) line and obtain samples for weekly laboratory tests. In our center, we routinely order weekly CBCs with differential, CMPs and urine analyses (UA) with microscopy for all OPAT patients. In addition, we order specific serum drug levels for patients on vancomycin or aminoglycoside and creatinine kinase (CK) levels for patients on daptomycin weekly. Infectious disease (ID) fellows review laboratory results regularly and follow patients in the clinic under the supervision of ID attendings.
Data collection: After approval from the Institutional Review Board, we collected clinical information from our institution’s electronic medical records. The data collected included age, gender, comorbidities, indications for OPAT, microbiology, prescribed antibiotics, OPAT duration, discharge location, time from discharge to outpatient clinic follow up, baseline laboratory abnormalities and the type and number of abnormal laboratory results while receiving OPAT. If patients were readmitted while receiving OPAT, we documented the date and reason for hospitalization. If the physician changed antibiotics, we documented the date of the change and reasons for the change.
Inclusion and exclusion criteria: The patients included in this study were 18 years old or older, required two weeks or more of OPAT and was evaluated by an infectious diseases consult team while in the hospital. We excluded those that entered hospice care, had missing data and were readmitted for more than one week for causes not directly related to antibiotic treatment or abnormal OPAT follow-up results.
Definitions and Variables: We separated patients into a cohort of OPAT patients with complications and patients with no complications. We defined an OPAT complication as a clinically significant laboratory abnormality, a need to change antibiotic class and hospital readmission for any reason. We defined immunosuppression as chronic glucocorticoid use, acquired immunodeficiency syndrome with CD4 < 200/mL, use of disease-modifying antirheumatic drugs (DMARD), solid organ transplant or bone marrow transplant. We used the Charlson comorbidity index (CCI) to estimate a 10-year mortality risk. The OPAT duration was the number of weeks from hospital discharge until the physician discontinued antibiotics. Laboratory values at initial discharge from the hospital were considered baseline. Clinically significant laboratory values included creatinine, sodium, potassium, aspartate aminotransferase, alanine transaminase, alkaline phosphatase, total white blood count, platelet count, absolute eosinophil count, vancomycin trough, CK and urinalysis.
Statistical Analysis: Continuous variables are reported in medians and interquartile ranges (IQRs). Nominal and categorical variables are reported as proportions and frequencies. Univariate analysis with Chi square test of independence was used to identify the risk factors of OPAT complications. Variables with a p value < 0.05 from the univariate analysis were included for the multivariable logistic regression model. We considered a p value < 0.05 statistically significant for our regression model. IBM SPSS 26 was used for the analysis.
5. Conclusions
Complications are not uncommon in OPAT patients. Recognizing predictors of OPAT complications will help determine strategies to optimize care, increase patient satisfaction and potentially further decrease cost. The less frequent monitoring of laboratory values could be useful in OPAT patients at a lower risk of complications. Less-frequent laboratory testing could be important to reduce costs (e.g., nursing effort to draw blood, laboratory cost and physician time to follow results) and potentially increase patient satisfaction (e.g., less blood draw).
Author Contributions
Conceptualization, G.A.; methodology, G.A., J.F., N.A. and S.N.; formal analysis, J.F. and S.N.; data curation, G.A., J.F. and N.A.; writing, J.F., G.A., N.A. and S.N.; supervision, G.A. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
This study was approved by the Saint Louis Institutional Review Board.
Informed Consent Statement
This is a retrospective study based on a review of medical records. Data collection or reporting did not include patient identifiers.
Data Availability Statement
Data will be available upon request.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Norris, A.; Shrestha, N.; Allison, G.; Keller, S.; Bhavan, K.; Zurlo, J.; Hersh, A.; Gorski, L.; Bosso, J.; Rathore, M.; et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin. Infect. Dis. 2019, 68, e1–e35. [Google Scholar] [CrossRef]
- Rucker, R.W.; Harrison, G.M. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974, 54, 358–360. [Google Scholar] [CrossRef]
- Keller, S.C.; Williams, D.; Gavgani, M.; Hirsch, D.; Adamovich, J.; Hohl, D.; Gurses, A.P.; E Cosgrove, S. Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy. Clin. Infect. Dis. 2018, 66, 11–19. [Google Scholar] [CrossRef]
- Lee, B.; Tam, I., IV; Weigel, B.; Breeze, J.L.; Paulus, J.K.; Nelson, J.; Genève, M. Allison. Comparative outcomes of beta-lactam antibiotics in outpatient parenteral antibiotic therapy: Treatment success, readmissions and antibiotic switches. J. Antimicrob. Chemother. 2015, 70, 2389–2396. [Google Scholar] [CrossRef] [PubMed]
- Murphy, J.L.; Fenn, N.; Pyle, L.; Heizer, H.; Hughes, S.; Nomura, Y.; Child, J.; Parker, S.K. Adverse Events in Pediatric Patients Receiving Long-term Oral and Intravenous Antibiotics. Hosp. Pediatr. 2016, 6, 330–338. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.; Choe, P.G.; Song, K.-H.; Park, S.-W.; Kim, H.B.; Kim, N.J.; Kim, E.-C.; Park, W.B.; Oh, M.-D. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob. Agents Chemother. 2011, 55, 5122–5126. [Google Scholar] [CrossRef]
- Li, J.; Echevarria, K.L.; Hughes, D.W.; Cadena, J.A.; Bowling, J.E.; Lewis, J.S., 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 2014, 58, 5117–5124. [Google Scholar] [CrossRef]
- Schrank, G.M.; Wright, S.B.; Branch-Elliman, W.; LaSalvia, M.T. A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy. Infect. Control. Hosp. Epidemiol. 2018, 39, 947–954. [Google Scholar] [CrossRef] [PubMed]
- Shrestha, N.; Mason, P.; Gordon, S.M.; Neuner, E.; Nutter, B.; O’Rourke, C.; Rehm, S.J. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: A propensity score-matched cohort study. J. Antimicrob. Chemother. 2014, 69, 1407–1415. [Google Scholar] [CrossRef]
- Huck, D.; Ginsberg, J.; Gordon, S.M.; Nowacki, A.S.; Rehm, S.J.; Shrestha, N.K. Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme. J. Antimicrob. Chemother. 2014, 69, 228–233. [Google Scholar] [CrossRef] [Green Version]
- Mace, A.O.; McLeod, C.; Yeoh, D.; Vine, J.; Chen, Y.-P.; Martin, A.C.; Blyth, C.; Bowen, A. Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: A pre-post observational study. Arch. Dis. Child. 2018, 103, 165–169. [Google Scholar] [CrossRef]
- Rybak, M.J.; Lomaestro, B.M.; Rotscahfer, J.C.; Moellering, J.R.C.; Craig, W.A.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 2009, 49, 325–327. [Google Scholar] [CrossRef] [PubMed]
- Staples, J.A.; Ho, M.; Ferris, D.; Hayek, J.; Liu, G.; Tran, K.C.; Sutherland, J.M. Outpatient Versus Inpatient Intravenous Antimicrobial Therapy: A Population-Based Observational Cohort Study of Adverse Events and Costs. Clin. Infect. Dis. 2022, 75, 1921–1929. [Google Scholar] [CrossRef] [PubMed]
- Lai, A.; Tran, T.; Nguyen, H.M.; Fleischmann, J.; O Beenhouwer, D.; Graber, C.J. Outpatient parenteral antimicrobial therapy at large Veterans Administration medical center. Am. J. Manag. Care 2013, 19, e317–e324. [Google Scholar]
- Saillen, L.; Arensdorff, L.; Moulin, E.; Voumard, R.; Cochet, C.; Boillat-Blanco, N.; Gardiol, C.; de Vallière, S. Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 1387–1392. [Google Scholar] [CrossRef]
- Hatcher, J.; Costelloe, C.; Cele, R.; Viljanen, A.; Samarasinghe, D.; Satta, G.; Brannigan, E.; De Barra, E.; Sanderson, F.; Gilchrist, M. Factors associated with successful completion of outpatient parenteral antibiotic therapy (OPAT): A 10-year review from a large West London service. Int. J. Antimicrob. Agents 2019, 54, 207–214. [Google Scholar] [CrossRef]
- Ng, N.; Bailey, P.; Pryor, R.; Fung, L.; Veals, C.; Sabouri, K.; Reznicek, J. Experiences in outpatient parenteral antimicrobial therapy (OPAT): Barriers and challenges from the front lines. Antimicrob. Steward Healthc. Epidemiol. 2021, 1, e42. [Google Scholar] [CrossRef]
- Schmidt, M.; Hearn, B.; Gabriel, M.; Spencer, M.D.; McCurdy, L. Predictors of Unplanned Hospitalization in Patients Receiving Outpatient Parenteral Antimicrobial Therapy Across a Large Integrated Healthcare Network. Open Forum Infect. Dis. 2017, 4, ofx086. [Google Scholar] [CrossRef]
- Kaul, C.M.; Haller, M.; Yang, J.; Solomon, S.; Wang, Y.; Wu, R.; Meng, Y.; Pitts, R.A.; Phillips, M.S. Assessment of risk factors associated with outpatient parenteral antimicrobial therapy (OPAT) complications: A retrospective cohort study. Antimicrob. Steward. Heal. Epidemiol. 2022, 2, e183. [Google Scholar] [CrossRef] [PubMed]
- Wieland, B.W.; Marcantoni, J.R.; Bommarito, K.M.; Warren, D.K.; Marschall, J. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus. Clin. Infect. Dis. 2012, 54, 585–590. [Google Scholar] [CrossRef]
- Blumenthal, K.G.; Youngster, I.; Rabideau, D.J.; Parker, R.A.; Manning, K.S.; Walensky, R.P.; Nelson, S.B. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J. Allergy Clin. Immunol. 2015, 136, 1288–1294 e1. [Google Scholar] [CrossRef] [Green Version]
- Krueger, K.M.; LaCloche, L.; Stein, A.B.; Kates, R.; Murray, M.; Angarone, M.P. Risk Factors Associated With Nephrotoxicity During Outpatient Intravenous Vancomycin Administration. J. Pharm. Technol. 2022, 38, 10–17. [Google Scholar] [CrossRef]
- Hale, C.M.; Steele, J.M.; Seabury, R.W.; Miller, C.D. Characterization of Drug-Related Problems Occurring in Patients Receiving Outpatient Antimicrobial Therapy. J. Pharm. Pract. 2017, 30, 600–605. [Google Scholar] [CrossRef]
- Huggins, C.E.; Park, T.E.; Boateng, E.; Zeana, C. The Impact of a Standardized Discharge Process on 30-Day Readmissions for Patients on Outpatient Parenteral Antibiotic Treatment. Hosp. Pharm. 2022, 57, 107–111. [Google Scholar] [CrossRef] [PubMed]
- Shrestha, N.K.; Shrestha, J.; Everett, A.; Carroll, D.; Gordon, S.M.; Butler, R.S.; Rehm, S.J. Vascular access complications during outpatient parenteral antimicrobial therapy at home: A retrospective cohort study. J. Antimicrob. Chemother. 2016, 71, 506–512. [Google Scholar] [CrossRef] [PubMed]
- Wong, K.K.; Fraser, T.G.; Shrestha, N.K.; Fatica, C.; Deshpande, A. Low incidence of Clostridium difficile infection (CDI) in patients treated with outpatient parenteral antimicrobial therapy (OPAT). Infect. Control. Hosp. Epidemiol. 2015, 36, 110–112. [Google Scholar] [CrossRef] [PubMed]
- Donzé, J.; Lipsitz, S.; Bates, D.W.; Schnipper, J.L. Causes and patterns of readmissions in patients with common comorbidities: Retrospective cohort study. BMJ 2013, 347, f7171. [Google Scholar] [CrossRef]
- Hart, E.; Snape, S.; Thomson, R. Palliative outpatient parenteral antibiotic therapy: A review of 5 years of patient data. JAC Antimicrob. Resist. 2020, 2, dlaa052. [Google Scholar] [CrossRef]
- Duncan, C.J.A.; Barr, D.; Ho, A.; Sharp, E.; Semple, L.; Seaton, R.A. Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. J. Antimicrob. Chemother. 2013, 68, 1650–1654. [Google Scholar] [CrossRef] [Green Version]
Table 1.
Demographics of patients with or without any OPAT complications.
| OPAT Complications (n = 116) | No OPAT Complications (n = 130) | p Value | Multivariate Analysis aOR | Multivariate Analysis 95% Cl | |
|---|---|---|---|---|---|
| Age (median, IQR) | 54.5 (40–65) | 55 (42–65) | |||
| Gender (female) | 53 (45.7%) | 56 (43.1%) | 0.68 | ||
| Comorbidities | |||||
| Cardiovascular disease | 24 | 21 | 0.36 | ||
| Liver cirrhosis | 7 | 6 | 0.62 | ||
| CKD/ESRD | 12 | 13 | 0.93 | ||
| DM | 35 | 35 | 0.57 | ||
| Malignancy | 12 | 13 | 0.93 | ||
| Immunosuppression | 13 | 22 | 0.2 | ||
| Obesity | 19 | 21 | 0.96 | ||
| None | 27 | 47 | 0.03 | 0.9 | 0.43–1.9 |
| Carlson Comorbidity Index | |||||
| 0–4 | 88 (75.9%) | 115 (88.5%) | 0.009 | 0.39 | 0.2–0.77 |
| ≥5 | 28 (24.1%) | 15 (11.5%) | 0.009 | 2.21 | 1.11–4.43 |
| Indications for OPAT | |||||
| Abdominal Infection | 9 (7.8%) | 13 (10.0%) | 0.54 | ||
| CNS infection | 16 (13.8%) | 11 (8.5%) | 0.18 | ||
| Endocarditis | 10 (8.6%) | 11 (8.5%) | 0.61 | ||
| Vascular Infection | 8 (6.9%) | 7 (5.4%) | 0.62 | ||
| ENT infection | 1 (0.9%) | 6 (4.6%) | 0.08 | ||
| Genitourinary Infection | 1 (0.9%) | 10 (7.7%) | 0.01 | 0.1 | 0.01–1.01 |
| Bone and Joint infections | 67 (57.8%) | 59 (45.4%) | 0.052 | 1.1 | 0.6–2.1 |
| Skin–Soft Tissue Infection | 2 (1.7%) | 5 (0.32%) | 0.32 | ||
| Pulmonary Infection | 2 (1.7%) | 9 (6.9%) | 0.06 | ||
| Pathogen treated | |||||
| Gram-positive Bacteria | 40 (34.5%) | 51 (39.2%) | 0.44 | ||
| Gram-negative Bacteria | 11 (9.5%) | 11 (8.5%) | 0.78 | ||
| MRSA | 22 (19.0%) | 9 (6.9%) | 0.004 | 2.4 | 0.82–7.0 |
| Pseudomonas | 1 (0.9%) | 7 (5.4%) | 0.06 | ||
| MDR-gram negatives | 3 (2.6%) | 11 (8.5%) | 0.06 | ||
| Candida | 0 | 1 (0.8%) | 0.34 | ||
| Polymicrobial | 25 (21.6%) | 28 (21.5%) | 0.98 | ||
| None | 14 (12.1%) | 12 (9.2%) | 0.47 | ||
| Antibiotic class (es) | |||||
| Beta-lactams w/o vancomycin | 57 (49.1%) | 98 (75.4%) | <0.001 | 1.3 | 0.28–6.3 |
| Vancomycin + others | 56 (48.3%) | 26 (20.0%) | <0.002 | 2.8 | 0.57–13.9 |
| Daptomycin | 3 (2.6%) | 6 (4.6%) | 0.4 | ||
| Beta-lactams used | |||||
| Aztreonam | 1 | 0 | 0.3 | ||
| Cefazolin | 4 | 3 | 0.6 | ||
| Ceftriaxone | 15 | 60 | <0.001 | 0.47 | 0.24–0.91 |
| Cefepime | 17 | 17 | 0.72 | ||
| Ertapenem | 5 | 35 | <0.001 | 0.6 | 0.24–1.4 |
| Penicillin G | 2 | 6 | 0.2 | ||
| Ampicillin | 3 | 0 | 0.07 | ||
| Nafcillin | 10 | 8 | 0.46 | ||
| Piperacillin/Tazobactam | 5 | 3 | 0.38 | ||
| Aminoglycoside | 0 | 3 | 0.1 | ||
| Fluoroquinolone | 3 | 0 | 0.07 | ||
| metronidazole | 31 | 30 | 0.51 | ||
| Rifampin | 6 | 4 | 0.41 | ||
| Number of antibiotics | |||||
| 1 | 60 (51.7%) | 79 (60.8%) | 0.15 | ||
| 2 | 35 (30.2%) | 45 (34.6%) | 0.46 | ||
| 3 | 21 (18.1%) | 6 (4.6%) | 0.0007 | 2.0 | 0.7–5.9 |
| Duration of OPAT (weeks) | |||||
| 2–4 | 20 (17.2%) | 51 (39.2%) | 0.0001 | 0.37 | 0.23–0.77 |
| ≥5 | 96 (82.8%) | 79 (60.8%) | 0.0001 | 2.7 | 1.3–5.6 |
| Discharge Location | \ | ||||
| Home | 109 (93.2%) | 123 (94.6%) | 0.83 | ||
| SNF | 7 (6.8%) | 7 (5.4%) | 0.83 | ||
| Weeks from Discharge to Clinic | |||||
| None | 18 (15.5%) | 20 (15.4%) | 0.98 | ||
| 1 to 3 | 78 (67.3%) | 102 (78.5%) | 0.047 | 0.54 | 0.23–1.2 |
| 4 to 6 | 20 (17.2%) | 8 (6.1%) | 0.006 | 1.4 | 0.41–4.7 |
| Baseline Abnormal lab | |||||
| Anemia | 85 | 86 | 0.22 | ||
| Eosinophilia | 2 | 2 | 0.91 | ||
| Leukopenia | 4 | 3 | 0.59 | ||
| Thrombocytopenia | 6 | 5 | 0.61 | ||
| Resolving AKI | 4 | 7 | 0.46 | ||
| Transaminitis | 6 | 2 | 0.11 | ||
| None | 21 | 39 | 0.03 | 0.62 | 0.3–1.3 |
Table 2.
Total number of OPAT complications.
| Abnormal Labs | Hospitalization | Change in Antibiotic Class | |||
|---|---|---|---|---|---|
| CMP | 73 | AKI | 11 | vancomycin | 13 |
| CBC | 22 | Electrolyte abnormality | 5 | nafcillin | 5 |
| Vancomycin Trough | 61 | Drug Liver Injury | 1 | cefepime | 4 |
| Creatine Kinase | 2 | Anemia | 1 | rifampin | 2 |
| Drug rash on Labs | 2 | daptomycin | 2 | ||
| Drug rash not on labs | 3 | ampicillin | 1 | ||
| PICC line thrombosis | 6 | ||||
| New Infection | 8 | ||||
| Not OPAT | 5 | ||||
| Total | 168 | Total | 42 | Total | 27 |
Table 3.
Laboratory abnormalities and risk of hospital readmission while receiving OPAT.
| Hospitalized/Changed Antibiotic (N =52) | No Change or Hospitalization (n = 194) | Univariate Analysis p Value | aOR | 95% Cl | |
|---|---|---|---|---|---|
| Abnormal lab results (total) | 66 | 97 | |||
| CMP | 37 | 41 | <0.0001 | 3.3 | 1.5–7.4 |
| Abnormal serum creatinine | 15 | 7 | <0.0001 | ||
| Electrolyte abnormality | 17 | 28 | 0.002 | ||
| Elevated transaminases | 5 | 6 | 0.04 | ||
| CBC | 7 | 15 | 0.2 | ||
| Eosinophilia | 3 | 11 | 0.98 | ||
| Leukopenia | 2 | 3 | 0.3 | ||
| Anemia | 2 | 1 | 0.052 | ||
| High/low vanc level | 20 | 41 | 0.01 | 0.867 | 0.34–2.2 |
| Elevated CK | 2 | 0 | 0.008 | ||
| Abnormal lab by week | |||||
| 1 | 10 | 10 | 0.001 | 5.1 | 1.4–19.3 |
| 2 | 30 | 24 | <0.0001 | 4.02 | 1.5–10.8 |
| 3 | 8 | 18 | 0.2 | ||
| 4 | 11 | 20 | 0.01 | 2.2 | 0.67–7.04 |
| 5 | 3 | 17 | 0.48 | ||
| 6 | 5 | 9 | 0.17 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Frisby, J.; Ali, N.; Niemotka, S.; Abate, G. Usefulness of Routine Laboratory Tests for Follow up of Patients Receiving Outpatient Parenteral Antimicrobial Therapy Run by Infectious Diseases Fellows. Antibiotics 2023, 12, 330. https://doi.org/10.3390/antibiotics12020330
AMA Style
Frisby J, Ali N, Niemotka S, Abate G. Usefulness of Routine Laboratory Tests for Follow up of Patients Receiving Outpatient Parenteral Antimicrobial Therapy Run by Infectious Diseases Fellows. Antibiotics. 2023; 12(2):330. https://doi.org/10.3390/antibiotics12020330
Chicago/Turabian StyleFrisby, Jared, Naureen Ali, Samson Niemotka, and Getahun Abate. 2023. "Usefulness of Routine Laboratory Tests for Follow up of Patients Receiving Outpatient Parenteral Antimicrobial Therapy Run by Infectious Diseases Fellows" Antibiotics 12, no. 2: 330. https://doi.org/10.3390/antibiotics12020330
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
